NIH-funded research P01 program project

Preventing organ rejection by targeting memory immune cells

Official title: Project-002

Funded at University of Chicago · NIH-11528790 · Data updated 2026-11-12

Working to help people with organ transplants keep their new organs without lifelong immune-suppressing drugs by targeting stubborn memory immune cells.

Quick facts

Grant typeP01 program project
Study typeNIH-funded research
Funding institutionUniversity of Chicago
NIH-funded
Lab location1 site (Chicago, United States)
Project startJuly 17, 2012
Project endApril 30, 2028
Funding year2026
Award (this year)$1,141,324
NIH project number5P01AI097113-14
Project IDNIH-11528790 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates are people who have received or are awaiting organ transplants, especially those who are sensitized or have prior immune activation against donor tissue.

Less likely to help

People without organ transplants or whose graft problems come from surgical, vascular, or other non-immune causes are unlikely to benefit directly from this work.

What this research studies

As a transplant patient, you should know researchers are studying why some people's immune systems keep attacking new organs even when standard treatments are used. They focus on 'memory' T cells that remember past exposures and on a process called linked sensitization that spreads this resistance. The team uses laboratory experiments, animal models, and analysis of immune cells to see how these memory cells avoid the signals that normally put immune responses to sleep. Their aim is to find ways to block or reprogram these cells so more transplant recipients might stop taking long-term immunosuppression.

Why it matters

Potential benefit: If successful, this work could reduce the need for lifelong immunosuppressive drugs and lower the risk of organ rejection.

How similar studies have gone: Some small clinical approaches like combined stem cell–organ transplants or careful drug withdrawal have achieved tolerance in a few patients, but memory T cells remain a major unresolved barrier.

Where this research is happening

  • University of Chicago
    Chicago, United States
    Active

Researchers

  • Principal investigator: Alegre, Maria-Luisa — University of Chicago
  • Study coordinator: Alegre, Maria-Luisa

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.